Senhwa's Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Related Keywords

Australia ,Taiwan ,United States ,California ,Taipei ,T Ai Pei ,San Diego ,South Korea ,Canada ,Senhwa Pidnarulex ,Mei Hui Kuo ,Senhwa Biosciences ,Senhwa Bioscience ,Senhwa Biosciences Inc ,Drug Administration ,Prnewswire Senhwa Biosciences Inc ,Fast Track Designation ,Acting Chief Executive Officer ,Fast Track ,Accelerated Approval ,Priority Review ,Multi Center Expansion Study ,Breast Cancer ,Ovarian Cancer ,Pancreatic Cancer ,Prostate Cancer ,Molecular Cancer ,Homologous Recombination ,Business ,Health ,Pr Newswire ,Cancer ,Tumors ,